Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.

导出 OA

翻译打印收藏纠错

作者： Cloud P,Paweletz ^[1] ; Grace A,Heavey ^[1] ; Yanan,Kuang ^[1] ; Emily,Durlacher ^[2] ; Thian,Kheoh ^[3] ; Richard C,Chao ^[3] ; Alexander I,Spira ^[4] ; Konstantinos,Leventakos ^[5] ; Melissa L,Johnson ^[6] ; Sai-Hong Ignatius,Ou ^[7] ; Gregory J,Riely ^[8] ; Kenna,Anderes ^[3] ; Wenjing,Yang ^[3] ; James G,Christensen ^[3] ; Pasi A,Jänne ^[1]

作者单位： Belfer Center of Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[1] Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[2] Mirati Therapeutics, San Diego, California. ^[3] Virginia Cancer Specialists Research Institute, Fairfax, Virginia. ^[4] Department of Oncology, Mayo Clinic, Rochester, Minnesota. ^[5] Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee. ^[6] Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, California. ^[7] Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York. ^[8]

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));嘧啶类(Pyrimidines);突变(Mutation)

DOI 10.1158/1078-0432.CCR-23-0795

PMID 37279096

发布时间 2024-03-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交